Also, crizotinib was found to sensitize cetuximab-resistant KRAS mutant CRC cell lines LoVo, HCT116, and DLD1 to radiation therapy (Cuneo et al., 2019). This evidence concerns the gene KRAS and colorectal carcinoma.